CA3188286A1 - Formes cristallines de 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate et procedes de synthese - Google Patents

Formes cristallines de 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate et procedes de synthese

Info

Publication number
CA3188286A1
CA3188286A1 CA3188286A CA3188286A CA3188286A1 CA 3188286 A1 CA3188286 A1 CA 3188286A1 CA 3188286 A CA3188286 A CA 3188286A CA 3188286 A CA3188286 A CA 3188286A CA 3188286 A1 CA3188286 A1 CA 3188286A1
Authority
CA
Canada
Prior art keywords
compound
formula
composition
free base
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3188286A
Other languages
English (en)
Inventor
Neil Buckley
Dan BELMONT
Sarah Bethune
Krista DIAZ
Bryan HAUSER
Myoung Goo Kim
Kumar Kannan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of CA3188286A1 publication Critical patent/CA3188286A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des polymorphes d'un composé de formule (X). L'invention concerne également des compositions pharmaceutiques contenant des polymorphes dudit composé et des procédés de traitement d'états chez un sujet en fournissant des polymorphes dudit composé.
CA3188286A 2020-06-30 2021-06-28 Formes cristallines de 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate et procedes de synthese Pending CA3188286A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046120P 2020-06-30 2020-06-30
US202063046123P 2020-06-30 2020-06-30
US63/046,123 2020-06-30
US63/046,120 2020-06-30
PCT/US2021/039305 WO2022005928A1 (fr) 2020-06-30 2021-06-28 Formes cristallines de 2-[4- [(2,3,4-triméthoxyphényl)méthyl]pipérazin-1-yl]éthyl pyridine-3-carboxylate et procédés de synthèse

Publications (1)

Publication Number Publication Date
CA3188286A1 true CA3188286A1 (fr) 2022-01-06

Family

ID=79314883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3188286A Pending CA3188286A1 (fr) 2020-06-30 2021-06-28 Formes cristallines de 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate et procedes de synthese

Country Status (8)

Country Link
EP (1) EP4171233A1 (fr)
JP (1) JP2023532330A (fr)
KR (1) KR20230031320A (fr)
CN (1) CN116056711A (fr)
AU (1) AU2021299266A1 (fr)
CA (1) CA3188286A1 (fr)
IL (1) IL299547A (fr)
WO (1) WO2022005928A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235297A1 (fr) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Composés et méthodes pour augmenter l'efficacité du métabolisme cardiaque

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) * 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP4092013A1 (fr) * 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions et procédés pour augmenter l'efficacité du métabolisme cardiaque

Also Published As

Publication number Publication date
KR20230031320A (ko) 2023-03-07
EP4171233A1 (fr) 2023-05-03
JP2023532330A (ja) 2023-07-27
AU2021299266A1 (en) 2023-02-02
WO2022005928A1 (fr) 2022-01-06
CN116056711A (zh) 2023-05-02
IL299547A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
JP7174132B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
CN106715454A (zh) 烟酰胺核苷的结晶形式
CA2887540A1 (fr) Systeme cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal selectionnes
JPWO2007007628A1 (ja) アズレン系化合物のコリン塩結晶
US20220298117A1 (en) Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
TW201200511A (en) Crystalline salts of a potent HCV inhibitor
WO2022017478A1 (fr) Nouvelle forme cristalline de cyclohexane formamide et son procédé de préparation
US20230331677A1 (en) Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
TW201514165A (zh) Ｄ-葡萄糖醇，１-脫氧-１-（甲胺基）-，-１-（６-胺基-３，５-二氟吡啶-２-基）-８-氯-６-氟-１，４-二氫-７-（３-羥基氮雜環丁烷-１-基）-４-側氧基-３-喹啉羧酸的結晶形態與其製備程序
CA3188286A1 (fr) Formes cristallines de 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate et procedes de synthese
JP2013512199A (ja) アジルサルタン有機アミン塩、その製造方法及び使用
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
CN112638903A (zh) 舒欣啶盐
TW200900392A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
WO2016095650A1 (fr) Substance polymorphe de chlorhydrate de yonkenafil, son procédé de préparation, composition à base de ladite substance et utilisation deladite substance
WO2010111951A1 (fr) Cristaux de bromhydrate de prasugrel
WO2018085932A1 (fr) Nouvelles formes cristallines du lésinurad
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
JP7425482B2 (ja) イソキノリンスルホンアミドの新規な形態
CN109422723B (zh) 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
EP1674468A1 (fr) Polymorphes de l'hydrobromide de clopidogrel
JP2023552672A (ja) ヌクレオシド類似体の塩及びその結晶形、医薬組成物並びに用途
EA043571B1 (ru) Соли сулькардина
JP2021505602A (ja) 腎外髄質カリウムチャネル阻害剤の結晶形およびその調製方法